EU PV & PE Research Network Under the Framework Service Contract (Nr

Total Page:16

File Type:pdf, Size:1020Kb

EU PV & PE Research Network Under the Framework Service Contract (Nr EU PV & PE Research Network under the Framework service contract (nr. EMA/2015/27/PH) Study Protocol “Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU” Version: 01 November 2016 For EMA review Name Role Dr. Helga Gardarsdottir1,2 Protocol 1 lead Dr. Christiane Gasse3 Protocol 1 co-lead/AU Danish National Registers lead Dr. Rianne van den Ham1 Protocol 1 co-lead/CPRD Database lead Marietta Rottenkolber4 Protocol 2 co-lead/Bavarian Claims Database lead Dr. Consuelo Huerta5 Protocol 2 co-lead/BIFAP Database lead Dr. Elisa Martín Merino5 BIFAP Database co-lead Dr. Luisa Ibanez6 Protocol 2 lead/SIDIAP Database lead Dr. Mónica Sabaté6 Protocol 2 co-lead/SIDIAP Database co-lead Dr. Xavier Vidal6 Protocol 2 co-lead/SIDIAP database co-lead Dr. Patrick Souverein1 CPRD&Mondriaan Database lead Prof. Dr. Nicholas Moore7 French Claims Database lead Dr. HenrietteThisted Horsdal3 Co-investigator/Danish National Registers Dr. Dolores Montero5 Co-investigator/BIFAP database Dr. Rolf Groenwold1,2 Co-investigator/CPRD&Mondriaan Dr. Sven Schmiedl8 AOK NORDWEST lead Prof. Dr. Katrin Janhsen8 AOK NORDWEST co-lead Prof. dr. Olaf Klungel1,2 PI/coordinator of EU PV & PE Research Network Ms. Satu J Siiskonen1 Project manager of EU PV & PE Research Network 1. Universiteit Utrecht, Utrecht, The Netherlands (UU) 2. University Medical Center Utrecht, Utrecht, The Netherlands (UMCU) 3. Aarhus University, Aarhus, Denmark (AU) 4 Klinikum der Universität München, München, Germany (KUM) 5 Agencia Espanola de Medicamentos y Productos Sanitarios, Madrid, Spain (AEMPS) 6. Fundació Institut Català de Farmacologia (FICF), Barcelona, Spain. 7. Bordeaux Pharmacoepi, Université de Bordeaux, Bordeaux, France (UB) 8. Witten/Herdecke University, Witten, Germany (UW/H) Any amendments to and/or deviations from this protocol will be documented by the PI/coordinator of EU PV & PE Research Network. EMA/2015/27/PH Version 01 Nov 2016 2 TABLE OF CONTENTS 1 Context of the proposal ........................................................................................................................................ 5 2 Objectives ............................................................................................................................................................. 5 3 Methods ............................................................................................................................................................... 5 3.1 Data sources ................................................................................................................................................. 5 3.1.1 Mondriaan ............................................................................................................................................ 5 3.1.2 Danish National Registries .................................................................................................................... 6 3.1.3 Bavarian claims database ..................................................................................................................... 6 3.1.4 AOK NORDWEST ................................................................................................................................... 6 3.1.5 BIFAP ..................................................................................................................................................... 6 3.1.6 System for the Development of Research in Primary Care (SIDIAP) ..................................................... 7 3.1.7 Clinical Practice Research Datalink (UK) ............................................................................................... 7 3.1.8 French Claims database: EGB ............................................................................................................... 7 3.2 Period of valid data collection ...................................................................................................................... 8 3.2.1 CPRD/Mondriaan/BIFAP/SIDIAP ........................................................................................................... 8 3.2.2 Danish registers .................................................................................................................................... 8 3.2.3 Bavarian claims ..................................................................................................................................... 8 3.2.4 AOK NORDWEST ................................................................................................................................... 8 3.2.5 EGB ....................................................................................................................................................... 8 3.3 Ethical issues ................................................................................................................................................. 8 4 Feasibility .............................................................................................................................................................. 9 5 Study Designs ..................................................................................................................................................... 11 5.1 Descriptive studies ..................................................................................................................................... 11 5.1.1 Data Sources ....................................................................................................................................... 11 5.1.2 Descriptive study investigating the utilization of DOACs in NVAF patients (objective 2) ................... 11 5.1.3 Descriptive study investigating prescriber compliance with SmPC recommendations (objective 3) . 14 5.2 Cohort study ............................................................................................................................................... 17 5.2.1 Population and study period .............................................................................................................. 17 5.2.2 Outcome ............................................................................................................................................. 17 5.2.3 Exposure definition ............................................................................................................................. 17 5.2.4 Potential confounders ........................................................................................................................ 19 5.2.5 Effect modifiers (subgroups) ............................................................................................................... 19 5.2.6 Analysis ............................................................................................................................................... 19 6 Limitations .......................................................................................................................................................... 20 6.1 Limitations related to the data source. ...................................................................................................... 20 6.2 Limitations related to methodology. .......................................................................................................... 20 6.3 Methodological study on exposure misclassification. ................................................................................ 20 6.3.1 Study design ........................................................................................................................................ 20 6.3.2 Analysis ............................................................................................................................................... 21 7 References .......................................................................................................................................................... 22 8 Annexes .............................................................................................................................................................. 24 8.1 Annex I: Information about the study drugs, dosing and indication. ......................................................... 24 Table 8.1.1. Oral anticoagulants, ATC codes and DDD ................................................................................ 24 Table 8.1.2. CPRD product codes ................................................................................................................ 24 Table 8.1.3. Indications and product recommended dose according to SmPCs for dabigatran, rivaroxaban and apixaban (SmPC item 4.1) ..................................................................................................................... 27 Table 8.1.4. Codes for indication according to the SmPC section 4.1. ........................................................ 28 Table 8.1.5. Posology and method of administration (SmPC item 4.2) ....................................................... 29 8.2 Annex II: Information about contraindications (SmPC item 4.3), special warnings and precautions (SmPC item 4.4) and interactions (SmPC item 4.5). ..................................................................................................... 32 Table 8.2.1. Registered contraindications (SmPC item 4.3) ........................................................................ 32 Table
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Asymmetric Organocatalyzed Synthesis of Coumarin Derivatives
    Asymmetric organocatalyzed synthesis of coumarin derivatives Natália M. Moreira‡, Lorena S. R. Martelli‡ and Arlene G. Corrêa* Review Open Access Address: Beilstein J. Org. Chem. 2021, 17, 1952–1980. Centre of Excellence for Research in Sustainable Chemistry, https://doi.org/10.3762/bjoc.17.128 Department of Chemistry, Federal University of São Carlos, 13565-905 São Carlos, SP – Brazil Received: 08 March 2021 Accepted: 21 July 2021 Email: Published: 03 August 2021 Arlene G. Corrêa* - [email protected] This article is part of the thematic issue "New advances in asymmetric * Corresponding author ‡ Equal contributors organocatalysis". Keywords: Guest Editor: R. Šebesta asymmetric synthesis; green chemistry; 2H-chromen-2-one; organocatalysis © 2021 Moreira et al.; licensee Beilstein-Institut. License and terms: see end of document. Abstract Coumarin derivatives are essential scaffolds in medicinal and synthetic chemistry. Compounds of this class have shown important activities, such as anticancer and antiparasitic, besides the commercially available drugs. These properties led to the development of efficient and greener synthetic methods to achieve the 2H-chromen-2-one core. In this context, the advances in asymmetric organocatalyzed synthesis of coumarin derivatives are discussed in this review, according to the mode of activation of the catalyst. Introduction Coumarins are important naturally occurring plant constituents and display a wide range of pharmacological and biological ac- tivities, such as anticancer [1], antibacterial [2], and
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Reactivity and Alkylating Potential of Some O-Heterocycles
    Dpto. de Qu´ımica f´ısica Facultad de Ciencias Qu´ımicas PhD Thesis Chemical processes that can damage cellular DNA: Reactivity and alkylating potential of some O-heterocycles Supervisors: Author: Prf. Dr. Julio Casado Rafael Gomez´ Bombarelli Prf. Dr. Emilio Calle November 8, 2011 A Marta, Jose,´ Lali y Pepe en ningun´ orden en particular Departamento de Qu´ımica f´ısica Facultad de Ciencias Qu´ımicas The work reported here has been carried out in the Departamento de Qu´ımica f´ısica of the Universidad de Salamanca, under the advice of Prof. Dr. Julio Casado Linarejos and Prof. Dr. Emilio Calle Mart´ın. Rafael Gomez´ Bombarelli Emilio Calle Mart´ın Julio Casado Linarejos It’s been emotional. Big Chris Acknowledgements The author thanks the Spanish Ministerio de Educacion´ for a PhD fellowship (AP2006-01976) and financed research stays at the workgroups of Prof. Dr. Jose´ Rueff (Universidade Nova de Lisboa) and Prof. Dr. Franc¸ois Maurel (ITODYS, Paris-VII), who are also thanked for their hos- pitality. Financial support of the research reported in this work by the Ministerio de Ciencia e Innovacion´ (projects CTQ2010-18999, CTQ2007-63263, CTQ2004-05048), and the Junta de Castilla y Leon´ and European Regional Development Fund (project SA040A08) is also ac- knowledged. E. Bombarelli and J. Arenas are also thanked for their generous donation of CPU-time and resources. i Contents List of Figuresv List of Tables vii List of Schemes ix Abbreviations xi Preface xiii 1 Alkylating agents and the NBP Test: a review 1 1.1 Development of the method....................5 1.1.1 Early examples.......................5 1.1.2 The Epstein test.......................6 1.1.3 Biological samples......................7 1.1.4 Chromatography......................7 1.2 NBP as a DNA-model.......................8 1.2.1 Nucleophilicity of DNA....................8 1.2.2 Site selectivity......................
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Subarachnoid Haemorrhage
    Instrument No.48 of 1999 Revocation and Determination of Statement of Principles concerning SUBARACHNOID HAEMORRHAGE ICD-9-CM CODE: 430 Veterans’ Entitlements Act 1986 1. The Repatriation Medical Authority under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (the Act): (a) revokes Instrument No.384 of 1995; and (b) determines in its place the following Statement of Principles. Kind of injury, disease or death 2. (a) This Statement of Principles is about subarachnoid haemorrhage and death from subarachnoid haemorrhage. (b) For the purposes of this Statement of Principles, “subarachnoid haemorrhage” means bleeding into the subarachnoid space, including rupture into the subarachnoid space of an intracranial saccular aneurysm or arteriovenous malformation, attracting ICD- 9-CM code 430. This definition includes subarachnoid haemorrahage due to bleeding disorder from anticoagulant therapy or thrombolytic therapy and excludes haemorrhage due to other bleeding disorders, haemorrhage due to cerebral tumour, or haemorrhage due to trauma to the brain or to the skull. Page 1 of 6 of Instrument No.48 of 1999. Basis for determining the factors 3. The Repatriation Medical Authority is of the view that there is sound medical-scientific evidence that indicates that subarachnoid haemorrhage and death from subarachnoid haemorrhage can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces. Factors that must be related to service 4. Subject to clause 6, at least one of the factors set out
    [Show full text]
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al
    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
    [Show full text]